Come up with a name for your new list and we'll add to it:
ImmusanT raised a round of funding on September 11, 2018. Investors include
JDRF T1D Fund.
ImmusanT is focused on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that aim to improve diagnosis and treatment and return patients to a normal diet, goo…